DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates
DOMA Perpetual, an activist investor owning approximately 7.5% of Pacira BioSciences, has issued a letter to shareholders urging them to vote for its three nominees to the Board of Directors. DOMA contends that the current board and management are misleading investors about the true risks to the business, particularly regarding the company's reliance on the drug EXPAREL, which accounts for about 80% of Pacira's revenue. The company has already lost a significant patent lawsuit, resulting in a 38% loss of future EXPAREL revenues.
Key figures
- Net income
- -$93 million
- Sg a increase
- 25%
- Ceo compensation
- $28 million
- Exparel revenue loss
- 38%
- R d spending increase
- 44%
- Shareholder ownership
- 7.5%
- Net income loss 3 years
- $50.5 million
- Stock price decline 5 year
- 62%
- Stock price decline 10 year
- 54%
- Stock price decline since ceo
- 29%
- Executive compensation 2 years
- $121 million
- Stock based compensation increase
- 36%
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.